- Home
- ENSC vs ALLR Comparison
ENSC vs ALLR Comparison
Compare ENSC & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- ALLR
- Stock Information
- Founded
- ENSC 2003
- ALLR 2004
- Country
- ENSC United States
- ALLR United States
- Employees
- ENSC N/A
- ALLR N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- ALLR Health Care
- Exchange
- ENSC Nasdaq
- ALLR Nasdaq
- Market Cap
- ENSC 3.4M
- ALLR 4.0M
- IPO Year
- ENSC N/A
- ALLR N/A
- Fundamental
- Price
- ENSC $2.34
- ALLR $1.04
- Analyst Decision
- ENSC
- ALLR
- Analyst Count
- ENSC 0
- ALLR 0
- Target Price
- ENSC N/A
- ALLR N/A
- AVG Volume (30 Days)
- ENSC 5.0M
- ALLR 955.3K
- Earning Date
- ENSC 05-13-2025
- ALLR 05-09-2025
- Dividend Yield
- ENSC N/A
- ALLR N/A
- EPS Growth
- ENSC N/A
- ALLR N/A
- EPS
- ENSC N/A
- ALLR N/A
- Revenue
- ENSC $6,224,081.00
- ALLR N/A
- Revenue This Year
- ENSC N/A
- ALLR N/A
- Revenue Next Year
- ENSC N/A
- ALLR N/A
- P/E Ratio
- ENSC N/A
- ALLR N/A
- Revenue Growth
- ENSC 256.35
- ALLR N/A
- 52 Week Low
- ENSC $1.62
- ALLR $0.61
- 52 Week High
- ENSC $14.67
- ALLR $25.47
- Technical
- Relative Strength Index (RSI)
- ENSC 46.40
- ALLR 52.18
- Support Level
- ENSC $1.99
- ALLR $0.96
- Resistance Level
- ENSC $2.40
- ALLR $1.06
- Average True Range (ATR)
- ENSC 0.26
- ALLR 0.08
- MACD
- ENSC 0.02
- ALLR -0.01
- Stochastic Oscillator
- ENSC 28.00
- ALLR 29.63
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.